Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department
Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Moderna, with aid of TBWA\Chiat\Day, is making mRNA science exciting & accessible
With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...
FiercePharma12d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Benzinga.com11d
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
BofA Securities cuts Moderna's price target from $110 to $90 due to vaccine sales concerns. Moderna faces tough ...
Reuters on MSN11d
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Nov 8 (Reuters) - Moderna (MRNA.O), opens new tab said on Friday Canada's health regulator has approved its vaccine for ...
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential
Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...